IND World's Fair Line

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

Retrieved on: 
Monday, November 6, 2023

WALTHAM, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the presentation of six posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

Key Points: 
  • “Solid tumors are notoriously heterogenous, which may contribute to low response rates and limited duration of response following treatment with single-targeting TCR-T cell therapy.
  • TScan’s solid tumor program is designed to deliver multiplexed, enhanced TCR-T cell therapy to effectively address both target heterogeneity and HLA loss,” said Gavin MacBeath, Ph.D., Chief Executive Officer.
  • “TScan has initiated a screening protocol to test for target expression and the presence of HLA genes in patients’ tumors.
  • Using TargetScan, TScan has identified a novel B*07:02-restricted epitope in the cancer/testis antigen MAGE-C2 as a promising target for TCR-T therapy.

Bluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business development

Retrieved on: 
Thursday, September 21, 2023

He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.

Key Points: 
  • He will be a member of Bluejay’s Executive team, reporting to Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “I am delighted to welcome Chris to the senior leadership team at Bluejay”, stated Mrs. Chu.
  • “Chris has an outstanding track record in business & corporate development with both public and private biotech and pharma companies.
  • Before joining Bluejay, he served as VP, Business & Corporate development at LEXEO Therapeutics, where he led all business development, strategic transactions and played a significant role in the company’s capital raising activities.

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

Retrieved on: 
Monday, August 21, 2023

MALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported second quarter 2023 financial results along with a general business update.

Key Points: 
  • ET
    MALVERN, Pa., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported second quarter 2023 financial results along with a general business update.
  • This quarter, Ocugen plans to share updated data results on OCU400 from its Phase 1/2 clinical trial in patients with retinitis pigmentosa.
  • NeoCart® – Manufacturing facility construction for NeoCart is on target to be completed by the end of 2023, as planned.
  • ET tomorrow to discuss the financial results and recent business highlights.

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

Retrieved on: 
Wednesday, August 2, 2023

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the second quarter 2023 and business updates.

Key Points: 
  • Strengthened Executive Team with Appointments of Erick Lucera as Chief Financial Officer and Linda C. Burkly, Ph.D., as Chief Scientific Officer
    CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the second quarter 2023 and business updates.
  • The Editas team is excited and continues driving execution towards our goals,” commented Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.
  • ET to provide and discuss a corporate update and financial results for the second quarter of 2023.
  • To access the call, please dial 1-877-407-0989 (domestic) or 1-201-389-0921 (international) and ask for the Editas Medicine earnings call.

Bionomics Announces Key Leadership Updates to Drive U.S.-Focused Transformation and Next Stage of Strategic Growth

Retrieved on: 
Monday, July 3, 2023

Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.

Key Points: 
  • Mr. Fisher succeeds Errol De Souza, Ph.D., who remains on the Board as a Non-Executive Director.
  • Mr. Fisher commented, “On behalf of the Board, I would like to express my excitement for Bionomics’ prospects and confidence in the team being assembled.
  • “Collectively, Tim, Julie, and Atul bring over 50+ years of experience in the biopharma sector, and diverse expertise in developing and commercializing drug products.
  • His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice.

Sana Biotechnology Reports First Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Monday, May 8, 2023

Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.

Key Points: 
  • Sana is developing SC451, a hypoimmune-modified stem-cell derived islet cell therapy for patients with type 1 diabetes.
  • Expect initial data later this year from an investigator-sponsored trial transplanting hypoimmune-modified primary human islet cells into type 1 diabetes patients.
  • The goal of the study is to show cell survival and immune evasion without the need for any immunosuppression.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

Sana Biotechnology Announces the Appointment of Two Pioneers in Drug Discovery and Development to Lead its R&D Organization

Retrieved on: 
Monday, April 10, 2023

SEATTLE, April 10, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the appointments of two senior leaders to its research and development organization, Douglas E. Williams, Ph.D., as President of Research and Development, and Gary Meininger, M.D., as Chief Medical Officer. In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.

Key Points: 
  • In a planned transition, Sunil Agarwal, M.D., Chief Medical Officer, will leave the company after helping onboard these new executives.
  • In his career, he has participated in the development of over a dozen approved medicines across multiple therapeutic areas, including multiple blockbusters.
  • Dr. Meininger has over two decades of experience in drug development leadership, most recently at Vertex and previously at both Janssen and Merck.
  • He is currently the industry representative to the FDA’s Endocrine and Metabolic Drug Advisory Committee.

TScan Therapeutics Announces CEO Transition

Retrieved on: 
Friday, March 31, 2023

WALTHAM, Mass., March 31, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (“TScan” or “The Company”), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as acting Chief Executive Officer (CEO), effective March 28, 2023. He will continue to serve as Chief Scientific and Operating Officer. David Southwell has stepped down as CEO and member of the Board, effective March 27, 2023.

Key Points: 
  • David Southwell has stepped down as CEO and member of the Board, effective March 27, 2023.
  • Dr. MacBeath joined TScan in 2018.
  • Chairman of the Board Timothy Barberich, said, “On behalf of the Board, we look forward to working with Gavin to continue the important work underway at TScan.
  • As of December 31, 2022, TScan Therapeutics had cash and cash equivalents of $120.0 million, excluding $5.0 million of restricted cash.

Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, March 16, 2023

SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • SEATTLE, March 16, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the fourth quarter and year ended December 31, 2022.
  • Sana expects an investigator sponsor trial using primary human hypoimmune-modified islet cells transplanted in type 1 diabetes patients to begin later this year.
  • In 2022, Sana transitioned to a new manufacturing process for SG295 and renamed the product SG299 in connection with that transition.
  • A discussion of non-GAAP measures, including a reconciliation of GAAP and non-GAAP measures, is presented below under “Non-GAAP Financial Measures.”

TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones

Retrieved on: 
Wednesday, March 8, 2023

WALTHAM, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today reported financial results for the three months and full year ended December 31, 2022, and highlighted upcoming anticipated milestones.

Key Points: 
  • For the three months ended December 31, 2022, TScan Therapeutics reported a net loss of $18.7 million, compared to a net loss of $14.2 million for the 2021 Quarter.
  • As of December 31, 2022, TScan Therapeutics had cash and cash equivalents of $120.0 million excluding $5.0 million of restricted cash.
  • General and administrative expenses for the year ended December 31, 2022, were $20.4 million, compared to $13.8 million for the 2021 Period.
  • For the year ended December 31, 2022, TScan Therapeutics reported a net loss of $66.2 million, compared to a net loss of $48.6 million for the 2021 Period.